S2366 HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596730

CAS#: 127428-47-1 (HCl)

Description: S 2366 is a chromogenic substrate for Factor XI in plasma.


Chemical Structure

img
S2366 HCl
CAS# 127428-47-1 (HCl)

Theoretical Analysis

MedKoo Cat#: 596730
Name: S2366 HCl
CAS#: 127428-47-1 (HCl)
Chemical Formula: C22H31ClN8O6
Exact Mass: 502.2288
Molecular Weight: 538.99
Elemental Analysis: C, 49.03; H, 5.80; Cl, 6.58; N, 20.79; O, 17.81

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 72194-57-1 (free base)    

Synonym: S 2366; S-2366; S2366; S2366 HCl; S2366 hydrochloride

IUPAC/Chemical Name: (S)-N-((S)-5-guanidino-1-((4-nitrophenyl)amino)-1-oxopentan-2-yl)-1-((R)-5-oxopyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide hydrochloride

InChi Key: SLOZDSBFVMGNDJ-VNMUXGFYSA-N

InChi Code: InChI=1S/C22H30N8O6.ClH/c23-22(24)25-11-1-3-15(19(32)26-13-5-7-14(8-6-13)30(35)36)28-20(33)17-4-2-12-29(17)21(34)16-9-10-18(31)27-16;/h5-8,15-17H,1-4,9-12H2,(H,26,32)(H,27,31)(H,28,33)(H4,23,24,25);1H/t15-,16+,17-;/m0./s1

SMILES Code: O=C([C@H]1N(C([C@@H](CC2)NC2=O)=O)CCC1)N[C@@H](CCCNC(N)=N)C(NC3=CC=C([N+]([O-])=O)C=C3)=O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 538.99 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Li QQ, Yang FQ, Wang YZ, Wu ZY, Xia ZN, Chen H. Evaluation of thrombin inhibitory activity of catechins by online capillary electrophoresis-based immobilized enzyme microreactor and molecular docking. Talanta. 2018 Aug 1;185:16-22. doi: 10.1016/j.talanta.2018.03.049. Epub 2018 Mar 18. PubMed PMID: 29759183.

2: Lövgren A, Deinum J, Rosén S, Bryngelhed P, Rosén P, Hansson KM. Characterization of thrombin derived from human recombinant prothrombin. Blood Coagul Fibrinolysis. 2015 Jul;26(5):545-55. doi: 10.1097/MBC.0000000000000289. PubMed PMID: 25811451; PubMed Central PMCID: PMC4500656.

3: Geng Y, Verhamme IM, Messer A, Sun MF, Smith SB, Bajaj SP, Gailani D. A sequential mechanism for exosite-mediated factor IX activation by factor XIa. J Biol Chem. 2012 Nov 2;287(45):38200-9. doi: 10.1074/jbc.M112.376343. Epub 2012 Sep 7. PubMed PMID: 22961984; PubMed Central PMCID: PMC3488089.

4: Marcinkiewicz MM, Sinha D, Walsh PN. Productive recognition of factor IX by factor XIa exosites requires disulfide linkage between heavy and light chains of factor XIa. J Biol Chem. 2012 Feb 24;287(9):6187-95. doi: 10.1074/jbc.M111.291989. Epub 2011 Dec 29. PubMed PMID: 22207756; PubMed Central PMCID: PMC3307291.

5: Tormoen GW, Rugonyi S, Gruber A, McCarty OJ. The role of carrier number on the procoagulant activity of tissue factor in blood and plasma. Phys Biol. 2011 Dec;8(6):066005. doi: 10.1088/1478-3975/8/6/066005. Epub 2011 Nov 2. PubMed PMID: 22048420; PubMed Central PMCID: PMC3529913.

6: Su YC, Miller TN, Navaneetham D, Schoonmaker RT, Sinha D, Walsh PN. The role of factor XIa (FXIa) catalytic domain exosite residues in substrate catalysis and inhibition by the Kunitz protease inhibitor domain of protease nexin 2. J Biol Chem. 2011 Sep 9;286(36):31904-14. doi: 10.1074/jbc.M111.257527. Epub 2011 Jul 21. PubMed PMID: 21778227; PubMed Central PMCID: PMC3173081.

7: Zhu T, Ubhayasekera W, Nickolaus N, Sun W, Tingsborg S, Mowbray SL, Schedin-Weiss S. Zinc ions bind to and inhibit activated protein C. Thromb Haemost. 2010 Sep;104(3):544-53. doi: 10.1160/TH09-12-0862. Epub 2010 Jul 20. PubMed PMID: 20664913.

8: Sinha D, Marcinkiewicz M, Navaneetham D, Walsh PN. Macromolecular substrate-binding exosites on both the heavy and light chains of factor XIa mediate the formation of the Michaelis complex required for factor IX-activation. Biochemistry. 2007 Aug 28;46(34):9830-9. Epub 2007 Aug 4. PubMed PMID: 17676929.

9: Sinha D, Marcinkiewicz M, Lear JD, Walsh PN. Factor XIa dimer in the activation of factor IX. Biochemistry. 2005 Aug 2;44(30):10416-22. PubMed PMID: 16042419.

10: Zivelin A, Ogawa T, Bulvik S, Landau M, Toomey JR, Lane J, Seligsohn U, Gailani D. Severe factor XI deficiency caused by a Gly555 to Glu mutation (factor XI-Glu555): a cross-reactive material positive variant defective in factor IX activation. J Thromb Haemost. 2004 Oct;2(10):1782-9. PubMed PMID: 15456490.

11: Sinha D, Badellino KO, Marcinkiewicz M, Walsh PN. Allosteric modification of factor XIa functional activity upon binding to polyanions. Biochemistry. 2004 Jun 15;43(23):7593-600. PubMed PMID: 15182201.

12: Briseid K, Johannesen S. Kallikrein modification with affinity to IgG present in higher amounts than normal in plasma from patients with Crohn's disease. Scand J Clin Lab Invest. 2003;63(6):425-9. PubMed PMID: 14594323.

13: Fernández JA, Xu X, Liu D, Zlokovic BV, Griffin JH. Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis. 2003 May-Jun;30(3):271-6. PubMed PMID: 12737945.

14: Briseid K, Johannesen S. Part of purified human plasma kallikrein removed together with a remaining IgG fraction--immunoblot experiments and functional tests. Scand J Clin Lab Invest. 2002;62(1):21-4. PubMed PMID: 12002409.

15: Niimi S, Oshizawa T, Naotsuka M, Ohba S, Yokozawa A, Murata T, Hayakawa T. Establishment of a standard assay method for human thrombomodulin and determination of the activity of the Japanese reference standard. Biologicals. 2002 Mar;30(1):69-76. PubMed PMID: 11846431.

16: Mattsson C, Menschik-Lundin A, Nylander S, Gyzander E, Deinum J. Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro. Thromb Res. 2001 Dec 15;104(6):475-86. PubMed PMID: 11755958.

17: Rintelen C, Yegneswaran S, Griffin JH. Anticoagulant dysfunction of human Arg352Trp-activated protein C caused by defective factor Va inactivation. Thromb Haemost. 2001 Feb;85(2):274-9. PubMed PMID: 11246547.

18: Briseid K, Lygren I, Johannesen S, Marthinsen K. Removal of IgG from normal plasma and plasma from untreated patients with active Crohn's disease--effect on levels of contact factors. Scand J Clin Lab Invest. 2000 May;60(3):237-45. PubMed PMID: 10885496.

19: Minnema MC, Pajkrt D, Wuillemin WA, Roem D, Bleeker WK, Levi M, van Deventer SJ, Hack CE, ten Cate H. Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia. Blood. 1998 Nov 1;92(9):3294-301. PubMed PMID: 9787166.

20: Briseid K, Hoem NO, Johannesen S, Haug K. Amidolytic assay of factor XI in human plasma--significance of kallikrein for the activity measured. Thromb Res. 1995 May 1;78(3):239-50. PubMed PMID: 7631304.